Table 4.
Clinical trials employing omics technology on different diseases (adopted from clincaltrials.gov, accessed on 3 September 2022).
| Disease | Intervention/Treatment | Country | ID | Status | Outcome to Assess (in Relation to Metabolomics and Proteomics) |
|---|---|---|---|---|---|
| Prostate cancer | N/A | Taiwan | NCT03237026 | Recruiting (as of September 2022). | Biochemical recurrence or progression. |
| Hepatocellular Carcinoma | Procedure: surgical resection drug: adjuvant atezolizumab–bevacizumab Therapy |
Singapore | NCT05516628 | Recruiting (as of September 2022). | Biomarkers based on multi-omics (epigenomics, genomics, transcriptomics, immunomics, proteomics, and metabolomics) and spatial tumor microenvironment profiles of both tissue and peripheral blood that predict therapy response. |
| Urothelial Carcinoma | Biomarkers and proteomics | Italy | NCT04770974 | Not yet recruiting (as of September 2022). | Bladder cancer’s metabolomic profile. |
| Pancreatic Neoplasms | Diagnostic test: soluble biomarkers dosage | France | NCT04370574 | Recruiting (as of September 2022). | To identify biomarkers that seem to be prognostically significant on overall survival or disease independent in pancreatic cancer patients. |
| Metastatic Urothelial Carcinoma | N/A | Taiwan | NCT04641936 | Recruiting (as of September 2022). | To discover possible metabolite and protein indicators capable of predicting the success and side effects of immuno–oncology-based therapies. |
| Adrenal Neoplasm Endocrine Tumors Neuroblastoma Parathyroid Neoplasms Thyroid Neoplasms |
N/A | Unites States | NCT01005654 | Recruiting (as of September 2022). | To create a metabolomic, proteomic, genetic, and epigenetic profile of endocrine neoplasm that would allow discriminating between benign and malignant tumors in each of the endocrine histologies under investigation. |
| Metastatic Renal Cell Carcinoma | N/A | Taiwan | NCT04712305 | Recruiting (as of September 2022). | To discover possible metabolite and protein indicators capable of predicting the success and side effects of immuno–oncology-based therapies. |
| Significant Prostate Cancer | Dietary supplement: multi-carotenoids (MCS) | Taiwan | NCT03237702 | Recruiting (as of September 2022). | Evaluating the effect of urine omics tests (metabolomics and proteomics) in participants undergoing or having undergone prostate biopsy and/or subsequent MCS supplementing |
| Colorectal Cancer (CRC) | N/A | United States | NCT00898378 | Completed | Utilize biological samples from patients with CRC or colorectal adenomatous polyps, as well as those without polyps, to perform genomic, metabolomic, lipidomic, glycoproteomic, and proteomic profiling to create an omic profile. |
| Sarcoma Endocrine Tumors Neuroblastoma Retinoblastoma Renal Cancer |
N/A | United States | NCT01109394 | Recruiting (as of September 2022). | To conduct on tumor and normal tissues, systematic molecular, genomic, proteomic, metabolomic, and other high throughput (Omics) profiling. |
| Extrapulmonary Small Cell Cancer Non-Small Cell Lung Cancer Small Cell Lung Cancer Pulmonary Neuroendocrine Tumors Thymic Epithelial Tumors |
N/A | United States | NCT02146170 | Recruiting (as of September 2022). | Conduct genomic, proteomic, and immunological investigations on blood, tumor, bodily fluid, and normal tissue to identify new therapeutic drugs, innovative treatment techniques, and new prognostic and diagnostic markers. |
| Thyroid Nodule Thyroid Cancer |
Diagnostic test: multi-omic analyses of blood and surgical specimens | Italy | NCT05428371 | Not yet recruiting (as of September 2022). | Identification of biomarkers of thyroid carcinoma. |
| Cutaneous Squamous Cell Carcinoma Basal Cell Carcinomas |
Biopsy | France | NCT04389112 | Recruiting (as of September 2022). | Metabolic profiling of the carcinogenesis stages of glycolysis, oxidative phosphorylation. |